1. Home
  2. WLK vs GH Comparison

WLK vs GH Comparison

Compare WLK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Corporation

WLK

Westlake Corporation

HOLD

Current Price

$99.94

Market Cap

11.5B

Sector

Industrials

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$104.95

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLK
GH
Founded
1986
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5B
13.3B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
WLK
GH
Price
$99.94
$104.95
Analyst Decision
Buy
Strong Buy
Analyst Count
15
21
Target Price
$90.07
$102.81
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
02-24-2026
02-19-2026
Dividend Yield
2.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,480,000,000.00
$902,569,000.00
Revenue This Year
N/A
$35.23
Revenue Next Year
$0.60
$27.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.38
52 Week Low
$56.33
$34.88
52 Week High
$118.23
$120.74

Technical Indicators

Market Signals
Indicator
WLK
GH
Relative Strength Index (RSI) 68.10 45.64
Support Level $96.68 $100.26
Resistance Level $103.00 $108.51
Average True Range (ATR) 4.26 5.98
MACD 0.89 -1.09
Stochastic Oscillator 84.26 31.71

Price Performance

Historical Comparison
WLK
GH

About WLK Westlake Corporation

Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: